c-MET kinase inhibitors: a patent review (2011 – 2013)

Bibliography

• Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25
   PubMed Web of Science ®Google Scholar
• Knudsen BS, Vande Woude G. Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev 2008;18:87-96
   PubMed Web of Science ®Google Scholar
• Maulik G, Shrikhande A, Kijima T, et al. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002;13:41-59
   PubMed Web of Science ®Google Scholar
• Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984;311:29-33
   PubMed Web of Science ®Google Scholar
• Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005;225:1-26
   PubMed Web of Science ®Google Scholar
• Porter J. Small molecule c-Met kinase inhibitors: a review of recent patents. Expert Opin Ther Patent 2010;20:159-77
   PubMed Web of Science ®Google Scholar
• Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003;63:7345-55
   PubMed Web of Science ®Google Scholar
• Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 2006;12:3657-60
   PubMed Web of Science ®Google Scholar
• Davis IJ, McFadden AW, Zhang Y, et al. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res 2010;70:639-45
   PubMed Web of Science ®Google Scholar
• Di Renzo MF, Olivero M, Martone T, et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000;19:1547-55
   PubMed Web of Science ®Google Scholar
• Park WS, Dong SM, Kim SY, et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 1999;59:307-10
   PubMed Web of Science ®Google Scholar
• Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73
   PubMed Web of Science ®Google Scholar
• Rickert KW, Patel SB, Allison TJ, et al. Structural basis for selective small molecule kinase inhibition of activated c-Met. J Biol Chem 2011;286:11218-25
   PubMedGoogle Scholar
• Liang Z, Ding X, Ai J, et al. Discovering potent inhibitors against c-Met kinase: molecular design, organic synthesis and bioassay. Org Biomol Chem 2012;10:421-30
   PubMedGoogle Scholar
• Matsumoto K, Nakamura T. NK4 gene therapy targeting HGF-Met and angiogenesis. Front Biosci 2008;13:1943-51
   PubMedGoogle Scholar
• Du L, Ai J, Li D, et al. Aspergiolides C and D: spirocyclic aromatic polyketides with potent protein kinase c-Met inhibitory effects. Chemistry (Easton) 2011;17:1319-26
   PubMed Web of Science ®Google Scholar
• Shanghai institute of materia medica, Chinese academy of sciences. Quinolines compounds, their preparation methods, pharmaceutical compositions containing the same and use thereof. WO2011022928; 2011
   Google Scholar
• Wang Y, Ai J, Wang Y, et al. Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent. J Med Chem 2011;54:2127-42
   PubMed Web of Science ®Google Scholar
• Porter J, Lumb S, Lecomte F, et al. Discovery of a novel series of quinoxalines as inhibitors of c-Met kinase. Bioorg Med Chem Lett 2009;19:397-400
   PubMed Web of Science ®Google Scholar
• Ascepion Pharmaceuticals, Inc. 5,6-Bicyclic Heteroaryl-Containing urea compounds as kinase inhibitors. WO2011023081; 2011
   Google Scholar
• Ascepion Pharmaceuticals, Inc. Deuterium-enriched heterocyclic compounds as kinase. WO2012028106; 2012
   Google Scholar
• Dussault I, Bellon SF. From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer. Anticancer Agents Med Chem 2009;9:221-9
   PubMed Web of Science ®Google Scholar
• Aix-Marseille University. Aminoacid derivatives, their process of preparation and their therapeutical uses as inhibitors of oncogenic signals by the met family. WO2011036303; 2011
   Google Scholar
• Cossart P. Met, the HGF-SF receptor: another receptor for Listeria monocytogenes. Trends Microbiol 2001;9:105-7
   PubMedGoogle Scholar
• Veiga E, Cossart P. Listeria InlB takes a different route to met. Cell 2007;130:218-19
   PubMedGoogle Scholar
• Patane S, Pietrancosta N, Hassani H, et al. A new Met inhibitory-scaffold identified by a focused forward chemical biological screen. Biochem Biophys Res Commun 2008;375:184-9
   PubMed Web of Science ®Google Scholar
• Furlan A, Colombo F, Kover A, et al. Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling. Eur J Med Chem 2012;47:239-54
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Co. Compounds useful as c-MET inhibitor. US8268836; 2011
   Google Scholar
• Eli Lilly and Co. Amidophenoxyindazoles useful as inhibitors of c-Met. USRE43878; 2011
   Google Scholar
• Vertex Pharmaceuticals, Inc. Aminopyrazole triazolothiadiazole inhibitors of c-met protein kinase. US20110124684; 2011
   Google Scholar
• Vertex Pharmaceuticals, Inc. c-MET protein kinase inhibitors. US8518938; 2011
   Google Scholar
• Incyte Corp. Imidazo[l,2-b][l,2,4]triazines as c-MET Inhibitors. WO2011162835; 2011
   Google Scholar
• Incyte Corp. Triazolotriazines as kinase inhibitors. US8143251; 2011
   Google Scholar
• Zhejiang Beta Pharma, Inc. Novel fused heterocyclic derivatives useful as c-MET tyrosine kinase inhibitors. WO2012006960; 2012
   Google Scholar
• Advenchen Laboratories, LLC. Compounds as c-MET kinase inhibitors. WO2012034055; 2012
   Google Scholar
• Xcovery Holding Co., LLC. Substituted pyridazine carboxamide compounds as kinase inhibitor compounds. WO2012048258; 2012
   Google Scholar
• Novartis. [1,2,4]Triazolo[4,3-B]Pyridazine compounds as inhibitors of the c-MET tyrosine kinase. WO2012107500; 2012
   Google Scholar
• Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors. US20120264735; 2012
   Google Scholar
• Merk Sharp & Dohme Corp. Tyrosine kinase inhibitors. WO2012009194; 2012
   Google Scholar
• Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors. WO2012030633; 2012
   Google Scholar
• Merck Sharp & Dohme Corp. Crystalline hydrochloride salts of c-MET kinase inhibitors. WO2011041157; 2011
   Google Scholar
• Merck & Co., Inc. Tyrosine kinase inhibitors. WO2008008310; 2008
   Google Scholar
• OSI Pharmaceuticals, LLC. Fused bicyclic kinase inhibitors. WO2012158658; 2012
   Google Scholar
• OSI Pharmaceuticals, LLC. Fused bicyclic kinase inhibitors. WO2011143646; 2011
   Google Scholar
• Shanghai Huilun Life Science & Technology Co., Ltd. A heterocyclic [B]Pyridone compound, intermediates thereof, method of preparation and uses. WO2012167600; 2012
   Google Scholar
• Beta Pharm Canada, Inc. Spirocyclic molecules as protein kinase inhibitors. WO2013013308; 2013
   Google Scholar
• Cephalon, Inc. Uracil derivatives as Axl and c-MET kinase inhibitors. WO2013074633; 2013
   Google Scholar
• Merck Patent Gesellschaft Mit Beschraenkter Haftung. 2-(Heterocyclylbenzyl)pyridazinone derivatives. US20130131037; 2013
   Google Scholar
• Liu X, Newton RC, Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med 2010;16:37-45
   PubMed Web of Science ®Google Scholar
• Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007;6:3314-22
   PubMed Web of Science ®Google Scholar
• Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67:4408-17
   PubMed Web of Science ®Google Scholar
• Timofeevski SL, McTigue MA, Ryan K, et al. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry 2009;48:5339-49
   PubMed Web of Science ®Google Scholar
• Underiner TL, Herbertz T, Miknyoczki SJ. Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates. Anticancer Agents Med Chem 2010;10:7-27
   PubMedGoogle Scholar
• Eder JP, Vande Woude GF, Boerner SA, et al. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009;15:2207-14
   PubMed Web of Science ®Google Scholar
• Liu X, Wang Q, Yang G, et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res 2011;17:7127-38
   PubMed Web of Science ®Google Scholar
• Ohashi K, Sequist LV, Arcila ME, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci USA 2012;109:E2127-33
   PubMed Web of Science ®Google Scholar
• Ohashi K, Sequist LV, Arcila ME, et al. Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res 2013;19:2584-91
   PubMed Web of Science ®Google Scholar
• Liu L, Greger J, Shi H, et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 2009;69:6871-8
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lee JC, Lin L, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012;44:852-60
   PubMed Web of Science ®Google Scholar
• Tiedt R, Degenkolbe E, Furet P, et al. A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. Cancer Res 2011;71:5255-64
   PubMed Web of Science ®Google Scholar
• Zhang Y, Guessous F, Kofman A, et al. XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs 2010;13:112-21
   PubMed Web of Science ®Google Scholar
• Samadi AK, Bazzill J, Zhang X, et al. Novel withanolides target medullary thyroid cancer through inhibition of both RET phosphorylation and the mammalian target of rapamycin pathway. Surgery 2012;152:1238-46
   PubMed Web of Science ®Google Scholar
• The IASLC 13th World Conference on Lung Cancer. Clinical responses to MP-470, an oral RAD51 inhibitor, in combination with standard of care doublet chemotherapy, in patients with SCLC and NE malignancies: a phase 1 case series. IASLC 13th World Conference; San Francisco; 2009
   Google Scholar
• Kollmannsberger CK, Hurwitz H, Vlahovic G, et al. Phase I study of daily administration of MGCD265 to patients with advanced malignancies (Study 265-101). J Clin Oncol 2009;27:e14525
   Google Scholar
• Schroeder GM, An Y, Cai ZW, et al. Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl) -2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J Med Chem 2009;52:1251-4
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kaplan-Lefko PJ, Rex K, et al. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo. Cancer Res 2008;68:6680-7
   PubMed Web of Science ®Google Scholar
• Mughal A, Aslam HM, Sheikh A, et al. c-Met inhibitors. Infect Agent Cancer 2013;8:13
   PubMedGoogle Scholar
• Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin 2009;59:111-37
   PubMed Web of Science ®Google Scholar
• Hornberg JJ, Bruggeman FJ, Westerhoff HV, et al. Cancer: a systems biology disease. Biosystems 2006;83:81-90
   PubMed Web of Science ®Google Scholar
• Knox SS. From 'omics' to complex disease: a systems biology approach to gene-environment interactions in cancer. Cancer Cell Int 2010;10:11
   PubMedGoogle Scholar
• Azmi AS. Network pharmacology: an emerging field in cancer drug discovery). Curr Drug Discov Technol 2013;10:93-4
   PubMedGoogle Scholar
• Azmi AS. Network pharmacology for cancer drug discovery: are we there yet? Fut Med Chem 2012;4:939-41
   PubMed Web of Science ®Google Scholar